Dermatology is entering a "biological revolution," with engineered tissues and bio-machines offering new therapeutic ...

The US biosimilar market evolves with 90 approvals, significant price drops, and new PBM models enhancing access to ...

As Northeastern Pennsylvania’s health care system grows more fragile, Rep. Rob Bresnahan deserves credit for confronting one of the root causes. In the<a href=" target="_blank"> December 3 Times ...

PBMs' slim profit margins may be strongly influenced by their accounting practices, and widespread industry consolidation has made assessing PBM profitability more difficult.

Psyence Biomedical Ltd. (Nasdaq: PBM) ('Psyence BioMed” or the 'Company”) today announced that it adjourned its annual and special meeting of shareholders (the 'Meeting”) until February 12, 2026.

Pharmacy benefit managers (PBMs) under the microscope for their role in high drug prices have often cited their reportedly ...

Psyence Biomedical Ltd. (Nasdaq: PBM) ('Psyence BioMed” or the 'Company”), today announced that it has decided to postpone the previously announced effective date of its reverse stock split of its ...

Psyence Biomedical (PBM) has announced the effective date of its 1-for-6.25 reverse stock split of the company's issued and outstanding common shares. The common shares are expected to begin trading ...

The Company's common shares are expected to begin trading on a post-consolidated basis at the opening of the market on February 2, 2026. Following the consolidation, the Company's common shares will ...

Bioproducts and biomaterials for repairing large bone defects hold significant promise in translational research, particularly within Medicine and Dentistry. This study investigated a novel biocomplex ...